Daré Bioscience Announces Effective License and Collaboration Agreement

Daré Bioscience (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it has met the funding requirement for obtaining an exclusive worldwide license to advance SST-6007 (5% Topical Sildenafil Citrate Cream), a potential treatment for Female Sexual Arousal Disorder (“FSAD”). The funds will be used to advance SST-6007 (5% Topical Sildenafil Citrate Cream), a potential treatment for Female Sexual Arousal Disorder (“FSAD”), through the next phase of clinical development.

As quoted in the press release:

“The addition of Topical Sildenafil to our portfolio reflects our commitment to develop unique and differentiated products for women’s reproductive health, including contraception, sexual health and vaginal health.  Our innovative pipeline of products has the opportunity to unlock value for Daré’s equityholders and deliver medicines that are more aligned with women’s specific needs.  We continue actively identifying and evaluating additional candidates that, like Ovaprene™ in contraception and Topical Sildenafil for FSAD, have the potential to address important gaps in the treatment options, ” said Sabrina Martucci Johnson, President and CEO, Daré Bioscience.

Click here to read the full press release.